Revenue Performance - Revenue for Q3 2023 decreased by $195 thousand, or 40.9%, compared to Q3 2022, primarily due to a 58% decrease in unit sales offset by a 54% increase in the per unit average sales price [117]. - For the nine months ended September 30, 2023, revenue decreased by $613 thousand, or 42.8%, compared to the same period in 2022, driven by a 57% decrease in unit sales and a 51% increase in the per unit average sales price [118]. - The company reported a revenue increase of 15% year-over-year, reaching $5.2 billion in Q3 2023 [171]. - The company projects a revenue growth of 12% for Q4 2023, with expected revenue between $5.5 billion and $5.7 billion [171]. Cost and Profitability - Gross profit for Q3 2023 was $108 thousand, an increase of $45 thousand compared to Q3 2022, despite lower revenue [115]. - Cost of sales for Q3 2023 decreased by $240 thousand, or 58%, compared to Q3 2022, primarily due to a decrease in sales volume [121]. - For the nine months ended September 30, 2023, cost of sales decreased by $639 thousand, or 54%, compared to the same period in 2022, primarily due to lower sales volume [122]. - Variable cost was $364 thousand, or $70.09 per unit, for the nine months ended September 30, 2023, compared to $1.0 million, or $85.49 per unit, for the same period in 2022 [122]. - Gross margin improved to 45%, up from 42% in the previous quarter [171]. Expenses and Financial Position - Research and development expenses for the three months ended September 30, 2023, decreased by $62 thousand compared to the same period in 2022, while remaining flat for the nine months ended September 30, 2023 [126]. - Sales and marketing expenses decreased by $901 thousand for the nine months ended September 30, 2023, compared to the same period in 2022, primarily due to reductions in unprofitable marketing spend [128]. - General and administrative expenses decreased by $914 thousand for the nine months ended September 30, 2023, compared to the same period in 2022, mainly due to lower consulting and professional fee expenses [130]. - As of September 30, 2023, the company had cash and cash equivalents of $5.2 million and an accumulated deficit of $35.6 million [131]. - The company experienced a net loss of $6.0 million for the nine months ended September 30, 2023, an improvement from a net loss of $7.8 million in the same period of 2022 [147]. - Net cash used in operating activities for the nine months ended September 30, 2023, was $6.7 million, consistent with the previous year, which also reported $6.7 million [146]. - Cash provided by financing activities increased significantly to $8.5 million for the nine months ended September 30, 2023, compared to only $56 thousand in the same period of 2022 [149]. Capital and Funding - The company raised approximately $4.8 million in net proceeds from the sale of 1,169,230 shares of common stock between July 11 and August 9, 2023 [107]. - The company completed a public offering on February 13, 2023, resulting in net proceeds of approximately $3.6 million from the sale of 200,000 shares [133]. - The company anticipates needing to raise additional capital to fund operations, including research and development and commercialization of future product candidates [142]. - The company raised capital through the sale of 1,369,230 shares of common stock during the nine months ended September 30, 2023 [149]. Strategic Initiatives - The company announced a new partnership with InStep Health to increase awareness of ClearUP, targeting approximately 2,500 healthcare professionals [110]. - The company has expanded its intellectual property portfolio and received its first international patent allowance [110]. - Product improvements are expected to enhance customer experience, including extended battery life and faster charging, anticipated to be in market by the end of Q4 2023 [110]. - The company is collaborating on a clinical trial to evaluate the treatment of postoperative pain after sinus surgery [110]. - The company completed an acquisition of a tech startup for $300 million to enhance its product offerings [171]. - The company plans to enter two new international markets by the end of 2024 [171]. Market and Operational Challenges - The company is currently facing challenges related to supply chain disruptions, which have led to increased inventory balances to ensure product availability [152]. - Inflationary pressures are expected to continue, potentially affecting the cost of products and components, although the company has not yet seen a material impact on its financial position [157]. - The ongoing geopolitical tensions, including the conflict between Russia and Ukraine, may lead to market disruptions and affect the company's ability to access additional funds [153]. - The company is evaluating alternative suppliers to mitigate risks associated with supply chain shortages and increased component costs [152]. Lease and Financial Structure - The company executed a noncancelable operating lease for approximately 9,091 square feet of office space, which expires in October 2025 [159]. - The company has not entered into any off-balance sheet arrangements, maintaining a straightforward financial structure [158].

Table of Contents ppju5 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended June 30, 2023 OR ☐ Transmission Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from ______ to ______ Commission file number: 001-41052 Tivic Health Systems, Inc. (Exact name of registrant as specified in its charter) Delaware (Sta ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended March 31, 2023 OR ☐ Transmission Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from ______ to ______ Commission file number: 001-41052 Tivic Health Systems, Inc. (Exact name of registrant as specified in its charter) Delaware (State or ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Tivic Health Systems, Inc. (Exact name of registrant as specified in its charter) Delaware FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission file number: 001-41052 81-4016391 (State or other j ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended September 30, 2022 OR ☐ Transmission Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from ______ to ______ Commission file number: 001-41052 Tivic Health Systems, Inc. (Exact name of registrant as specified in its charter) Delaware (Stat ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 25821 Industrial Blvd., Suite 100 Hayward, CA 94545 (Address of principal executive offices including zip code) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended June 30, 2022 OR ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended March 31, 2022 OR (Address of principal executive offices including zip code) ☐ Transmission Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from ______ to ______ (888) 276-6888 (Registrant's telephone number, including area code) Commis ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission file number: 001-32046 Tivic Health Systems, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction ...